A Caltech Library Service

Fighting Cancer with Corroles

Teo, Ruijie D. and Hwang, Jae Youn and Termini, John and Gross, Zeev and Gray, Harry B. (2017) Fighting Cancer with Corroles. Chemical Reviews, 117 (4). pp. 2711-2729. ISSN 0009-2665. PMCID PMC6357784.

[img] PDF - Accepted Version
See Usage Policy.


Use this Persistent URL to link to this item:


Corroles are exceptionally promising platforms for the development of agents for simultaneous cancer-targeting imaging and therapy. Depending on the element chelated by the corrole, these theranostic agents may be tuned primarily for diagnostic or therapeutic function. Versatile synthetic methodologies allow for the preparation of amphipolar derivatives, which form stable noncovalent conjugates with targeting biomolecules. These conjugates can be engineered for imaging and targeting as well as therapeutic function within one theranostic assembly. In this review, we begin with a brief outline of corrole chemistry that has been uniquely useful in designing corrole-based anticancer agents. Then we turn attention to the early literature regarding corrole anticancer activity, which commenced one year after the first scalable synthesis was reported (1999–2000). In 2001, a major advance was made with the introduction of negatively charged corroles, as these molecules, being amphipolar, form stable conjugates with many proteins. More recently, both cellular uptake and intracellular trafficking of metallocorroles have been documented in experimental investigations employing advanced optical spectroscopic as well as magnetic resonance imaging techniques. Key results from work on both cellular and animal models are reviewed, with emphasis on those that have shed new light on the mechanisms associated with anticancer activity. In closing, we predict a very bright future for corrole anticancer research, as it is experiencing exponential growth, taking full advantage of recently developed imaging and therapeutic modalities.

Item Type:Article
Related URLs:
URLURL TypeDescription CentralArticle
Gray, Harry B.0000-0002-7937-7876
Additional Information:© 2016 American Chemical Society. Received: June 24, 2016. Publication Date (Web): October 19, 2016. Special Issue: Expanded, Contracted, and Isomeric Porphyrins. We have greatly enjoyed working with Lali Medina-Kauwe, Daniel Farkas, and many other colleagues on research discussed in this review. This work was supported by a Caltech-COH grant (J.T., H.B.G., and Z.G.), the AACR–Thomas J. Bardos Science Education Award (R.D.T.), the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2014R1A1A2054934, NRF-2014M3A9D7070668), and Samsung Research Funding for Future Technology (J.Y.H.). Research in the Beckman Institute Laser Center at Caltech was supported by NIH R01 DK019038, while research performed at Technion was supported by the Israel Science Foundation. The authors declare no competing financial interest.
Funding AgencyGrant Number
Caltech-City of Hope Biomedical InitiativeUNSPECIFIED
American Association for Cancer Research (AACR)UNSPECIFIED
National Research Foundation of KoreaNRF-2014R1A1A2054934
National Research Foundation of KoreaNRF-2014M3A9D7070668
NIHR01 DK019038
Israel Science FoundationUNSPECIFIED
Issue or Number:4
PubMed Central ID:PMC6357784
Record Number:CaltechAUTHORS:20161024-122920631
Persistent URL:
Official Citation:Fighting Cancer with Corroles Ruijie D. Teo, Jae Youn Hwang, John Termini, Zeev Gross, and Harry B. Gray Chemical Reviews 2017 117 (4), 2711-2729 DOI: 10.1021/acs.chemrev.6b00400
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:71389
Deposited By: George Porter
Deposited On:24 Oct 2016 19:43
Last Modified:22 Nov 2019 09:58

Repository Staff Only: item control page